循环肿瘤细胞检测的临床应用

国际肿瘤学杂志››2014,Vol. 41››Issue (2): 99-102.doi:10.3760/cma.j.issn.1673-422X.2014.02.007

李庞, 高杰, 李胜

250062 济南大学betway.com 医学与生命科学学院（李庞）；山东省烟台市毓璜顶医院肝胆外科（高杰）；betway.com 科技开发处（李胜）

收稿日期:2013-09-05修回日期:2013-12-04出版日期:2014-02-08发布日期:2014-01-26
通讯作者:李胜，E-mail: drlisheng@sohu.com E-mail:drlisheng@sohu.com
基金资助:

国家重点基础研究发展计划（973计划）项目（2011CB504302）

Clinical application of circulating tumor cells detection

Li Pang, Gao Jie, Li Sheng

College of Medical and Life Sciences, Shandong Academy of Medical Sciences, Ji′nan University, Ji′nan 250062, China

Received:2013-09-05Revised:2013-12-04Online:2014-02-08Published:2014-01-26
Contact:Li Sheng E-mail:drlisheng@sohu.com

摘要/Abstract

摘要：循环肿瘤细胞（CTC）计数在判断肿瘤的临床分期、评估肿瘤预后、进行疗效监测中的应用价值已获得广泛认可，但还需要大量研究来建立标准化评价体系并进行临床试验验证。CTC的分子生物学检测不仅可以对CTC计数进行完善，更因为其在肿瘤的辅助诊断和指导个体化治疗中的巨大潜力以及对于了解肿瘤转移的生物学行为的重大意义将成为未来的研究热点。

李庞, 高杰, 李胜. 循环肿瘤细胞检测的临床应用[J]. 国际肿瘤学杂志, 2014, 41(2): 99-102.

Li Pang, Gao Jie, Li Sheng. Clinical application of circulating tumor cells detection[J]. Journal of International Oncology, 2014, 41(2): 99-102.

［1］ Ilina O, Friedl P. Mechanisms of collective cell migration at a glance［J］. J Cell Sci, 2009, 122(Pt 18): 3203-3208. ［2］ Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with smallcell lung cancer［J］. J Clin Oncol, 2012, 30(5): 525-532. ［3］ Sun YF, Xu Y, Yang XR, et al. Circulating stem celllike epithelial cell adhesion moleculepositive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection［J］. Hepatology, 2013, 57(4): 14581468. ［4］ Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer［J］. Clin Cancer Res, 2009, 15(22): 6980-6986. ［5］ Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmallcell lung cancer［J］. J Clin Oncol, 2011, 29(12): 1556-1563. ［6］ Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and metaanalysis［J］. BMC Cancer, 2011, 11: 336. ［7］ Resel Folkersma L, San José Manso L, Galante Romo I, et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormonesensitive prostate cancer［J］. Urology, 2012, 80(6): 1328-1332. ［8］ Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors［J］. J Clin Oncol, 2013, 31(3): 365-372. ［9］ Blke E, Orth K, Gerber PA, et al. Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients［J］. Eur J Med Res, 2009, 14(8): 359-363. ［10］ Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study［J］. Eur Urol, 2012, 61(4): 810-817. ［11］ Hayashi N, Nakamura S, Tokuda Y, et al. Prognostic value of HER2positive circulating tumor cells in patients with metastatic breast cancer［J］. Int J Clin Oncol, 2012, 17(2): 96-104. ［12］ Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALKpositive nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(18): 2273-2281. ［13］ Khoja L, Lorigan P, Zhou C, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma［J］. J Invest Dermatol, 2013, 133(6): 1582-1590. ［14］ Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer［J］. J Thorac Oncol, 2012, 7(3): 512-519. ［15］ Matsusaka S, Chin K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer［J］. Cancer Sci, 2010, 101(4): 1067-1071. ［16］ Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stemlike cells, in peripheral blood for recurrence and prognosis in patients with Dukes′ stage B and C colorectal cancer［J］. J Clin Oncol, 2011, 29(12): 1547-1555. ［17］ Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelialmesenchymal transition and is associated with colorectal cancer prognosis［J］. Cancer Res, 2013, 73(7): 2059-2069. ［18］ Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications［J］. Ann Oncol, 2008, 19(5): 891-897. ［19］ Hartkopf AD, Wagner P, Wallwiener D, et al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer［J］. Anticancer Res, 2011, 31(3): 979-984. ［20］ Lu CY, Tsai HL, Uen YH, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage Ⅲ colon cancer［J］. Br J Cancer, 2013, 108(4): 791-797. ［21］ Jatana KR, Balasubramanian P, Lang JC, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results［J］. Arch Otolaryngol Head Neck Surg, 2010, 136(12): 1274-1279. ［22］ Contractor K, Aboagye EO, Jacob J, et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and ［(18)F］ 3′ deoxy3′fluorothymidine PET: a pilot study［J］. Biomark Med, 2012, 6(2): 231-233. ［23］ Pachmann K, Camara O, Kroll T, et al. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neupositive breast carcinoma［J］. J Cancer Res Clin Oncol, 2011, 137(9): 1317-1327. ［24］ Yin XD, Yuan X, Xue JJ, et al. Clinical significance of carcinoembryonic antigen, cytokeratin 19, or survivinpositive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy［J］. Dis Esophagus, 2012, 25(8): 750-756. ［25］ Somlo G, Lau SK, Frankel P, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage Ⅳ breast cancer, using a novel detection technology［J］. Breast Cancer Res Treat, 2011, 128(1): 155-163. ［26］ Sakaizawa K, Goto Y, Kiniwa Y, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level［J］. Br J Cancer, 2012, 106(5): 939-946. ［27］ Chen CL, Mahalingam D, Osmulski P, et al. Singlecell analysis of circulating tumor cells identifies cumulative expression patterns of EMTrelated genes in metastatic prostate cancer［J］. Prostate, 2013, 73(8): 813-826.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[7]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[8]	陈琦, 徐晨阳, 王寅, 雷大鹏.高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[9]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[10]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[12]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生.乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.